Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01868360
Other study ID # AMB65110
Secondary ID
Status Terminated
Phase Phase 1
First received May 15, 2013
Last updated October 5, 2015
Start date June 2013
Est. completion date October 2015

Study information

Verified date October 2015
Source University of Utah
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The cornea is the clear front part of the eye. Corneal neovascularization, the excessive growth of blood vessels into the cornea, is a sight-threatening condition. Corneal neovascularization is also a well recognized risk factor for corneal graft failure. The current standard of care to prevent graft rejection includes use of topical steroids and medicines that suppress the immune system. These medicines do not address corneal neovascularization. The purpose of the study is to establish the safety and potential efficacy of subconjunctival injections of aflibercept (EYLEA® , marketed by Regeneron) injection in inducing regression of blood vessels growing into the cornea and promoting graft survival.

This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center.


Description:

Corneal neovascularization is a sight threatening condition and is also a well recognized risk factor for corneal graft failure. Current standard of care to prevent graft rejection includes use of topical steroids and immunosuppressants. These do not address corneal neovascularization. The cornea is kept in its avascular state by a complex interaction of signal proteins and host receptors, with a vital role played by the soluble VEGF-receptor 1. In any condition of chronic corneal inflammation or hypoxia, the balance may tip in favour of pro-angiogenic factors, and neovascularization will ensue. Early and limited studies have examined the effect of subconjunctival or intracorneal administration of monoclonal antibodies to VEGF (bevacizumab, ranibizumab) in combating corneal neovascularization. Most report subtotal or temporary regression. The development of aflibercept (also known as VEGF Trap-Eye) offers new hope of more effectively combating the problem. In this study, research will be conducted to investigate and assess safety of subconjunctival aflibercept injection in patients with corneal neovascularization undergoing corneal transplantation.

This is a phase 1, prospective, randomized, open label clinical trial that will enroll 10 corneal transplant patients with corneal neovascularization in one or more quadrants crossing more than 0.5 mm over the limbus at the time of corneal transplantation.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

A patient must meet the following criteria to be eligible for inclusion in the study:

1. Candidates for corneal transplantation (only one eye per patient would be enrolled)

2. Patients with corneal neovascularization in one or more quadrants crossing more than 1.0 mm over the limbus at time of enrollment in the study

3. Willing and able to comply with clinic visits and study-related procedures

4. Provide signed informed consent

5. Age 18 or over

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from the study:

1. Patients receiving antiangiogenic anti-VEGF medication either systemically or intravitreally for other pathology or have received these drugs within 3 months of study enrollment

2. Patients with active corneal infection requiring additional treatment modalities

3. Patients receiving coumadin with INR >2.0, other anti-thrombotic agents (e.g., aspirin, Plavix) permitted at discretion of investigator

4. History of cerebrovascular accident or myocardial infarction within 6 months prior to study enrollment

5. Uncontrolled blood pressure- defined as SBP>160 mmHg or DBP >95mmHg while patient is sitting

6. Pregnant or breast-feeding women

7. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Subconjunctival aflibercept
subconjunctival aflibercept injection
Other:
Placebo: Standard of care only
Patients will receive standard of care (steroids and cyclosporine) treatment only.

Locations

Country Name City State
United States John A. Moran Eye Center Salt Lake City Utah

Sponsors (2)

Lead Sponsor Collaborator
Balamurali Ambati Regeneron Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (3)

Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001 Aug;12(4):242-9. Review. — View Citation

Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007. Review. — View Citation

The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992 Oct;110(10):1392-403. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety defined by incidence and severity of adverse events at week 28 The primary endpoint in the study is safety as defined by incidence and severity of adverse events in patients with corneal neovascularization undergoing corneal transplant. Week 28 Yes
Secondary neovascularization regression Ability of subconjunctival aflibercept injection to regress neovascularization at time of transplant and promote graft survival after corneal transplantation at time of transplant No
Secondary Need for immunosuppression Need for immunosuppression at week 28 in both treatment groups Week 28 No
Secondary Effect on corneal infections Effect on corneal infections or other side effects through week 28 in both treatment groups Through week 28 No
Secondary Change in visual acuity Change in ETDRS visual acuity from baseline at week 28 in both treatment groups Week 28 No
Secondary Mean number of injections Mean number of injections performed per patient through week 28 in patients receiving subconjunctival aflibercept injections Week 28 No
Secondary Rescue therapy Need for rescue treatment in the standard of care group through week 28 Week 28 Yes
Secondary neovascularization regression Ability of subconjunctival aflibercept injection to regress neovascularization (at 28 weeks after transplant) and promote graft survival after corneal transplantation at 28 weeks after transplant No
Secondary neovascularization regression Ability of subconjunctival aflibercept injection to regress neovascularization at 52 weeks after transplant and promote graft survival after corneal transplantation at 52 weeks after transplantation No
Secondary Need for immunosuppression need for immunosuppression at week 52 in both treatment groups week 52 No
Secondary Effect on corneal infections Effect on corneal infections or other side effects through week 52 in both treatment groups. Through week 52 No
Secondary Change in visual acuity Change in ETDRS visual acuity from baseline at week 52 in both treatment groups Week 52 No
Secondary Mean number of injections Mean number of injections performed per patient through week 52 in patients receiving subconjunctival aflibercept injections Week 52 No
Secondary Rescue therapy Need for rescue treatment in the standard of care group through week 52 Week 52 Yes
See also
  Status Clinical Trial Phase
Completed NCT00555594 - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Phase 2/Phase 3
Completed NCT00004430 - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization N/A
Completed NCT00769145 - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Phase 1
Completed NCT01257750 - Treatment of Corneal Neovascularization With Topical Pazopanib Phase 1/Phase 2
Recruiting NCT04787471 - Corneal Crosslinking for Treatment of Corneal Neovascularization Phase 2/Phase 3
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting NCT00992849 - Bevacizumab for the Treatment of Corneal Neovascularization Phase 2
Withdrawn NCT00515684 - Corneal Thinning During Topical Bevacizumab Therapy N/A
Terminated NCT02797704 - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Phase 1/Phase 2
Withdrawn NCT02042027 - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Phase 1
Recruiting NCT04215393 - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Phase 1
Completed NCT00797303 - The Effect of Bevacizumab on Corneal Neovascularization Phase 4
Recruiting NCT05659940 - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed NCT00559936 - Topical Avastin for Treatment of Corneal Neovascularization Phase 1
Completed NCT01072357 - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Recruiting NCT04620109 - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment Phase 1
Completed NCT00512876 - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization N/A
Recruiting NCT05011916 - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization Phase 1/Phase 2
Completed NCT01996826 - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Terminated NCT00915590 - Topical IL-1-Ra for Treatment of Corneal Neovascularization Phase 1/Phase 2